Title :

Factors associated with the variability of calcineurin inhibitor blood levels in kidney recipients grafted for more than 1 year

Author(s) :

Belaiche, Stephanie [Auteur]
Decaudin, Bertrand [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Dharancy, Sebastien [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Gautier, Sophie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Noel, Christian [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Odou, Pascal [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Hazzan, Marc [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Journal title :

Fundamental & clinical pharmacology

Abbreviated title :

Fundam. Clin. Pharmacol.

Volume number :

32

Pages :

88-97

Publication date :

2018-02-01

ISSN :

0767-3981

Keyword(s) :

calcineurin inhibitor blood levels
medication adherence
kidney transplantation
immunosuppressive drugs

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The study of calcineurin inhibitor (CNI) blood level variability to evaluate adherence in transplantation has improved over the years. The aim of our study was to assess factors associated with this variability using the ...
Show more >The study of calcineurin inhibitor (CNI) blood level variability to evaluate adherence in transplantation has improved over the years. The aim of our study was to assess factors associated with this variability using the coefficient of variation (CV). A cross-sectional sample of kidney recipients grafted for more than 1 year was recruited. We recorded clinical data, data from a clinical pharmacist interview and from six questionnaires measuring adherence, satisfaction, behaviours, beliefs, perception of the illness and social vulnerability. A total of 408 recipients were enrolled (61.2% male, mean age 54) and divided into two groups: low variability CV < 30% (n = 302), high variability CV ≥ 30% (n = 106). In univariate analysis, hospital-home distance, cyclosporine, time since transplantation and presence of discrepancies in drug regimen were associated with a greater risk of CV ≥ 30%. In contrast, tacrolimus QD conferred a lower risk of CV ≥ 30%. In multivariate analysis, only the presence of discrepancies remained significant: (OR 3.2 [1.21-9.01]; P = 0.022). Discrepancies in drug regimen appear as the main risk factor associated with CNI blood variability. The clinical pharmacist's input is an accurate and simple way of detecting non-adherence which is not revealed in self-report questionnaires.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille
Inserm

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Research team(s) :

Innovation/évaluation des médicaments injectables
Innovation/évaluation des dispositifs médicaux de perfusion
Inflammatory digestive disease : pathophysiology and therapeutic targets developement
Immunity, inflammation and fibrsis in auto and allo-reactivity

Submission date :

2019-02-26T17:07:04Z